Teclistamab plus your own immune cells for relapsed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new combination for multiple myeloma that has come back or not responded to earlier treatments. It uses a drug called teclistamab (which helps your immune system attack myeloma cells) along with an infusion of your own immune cells (lymphocytes) to potentially improve the response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back after treatment or did not respond to your last treatment.
- You have had 1 or 2 lines of treatment so far (counting induction, transplant, and maintenance as one line).
- You have already tried at least one drug from each of three groups: an immunomodulatory drug (like lenalidomide), a proteasome inhibitor (like bortezomib), and a monoclonal antibody (like daratumumab).
- You have measurable signs of myeloma in your blood or urine.
- You are generally able to care for yourself (ECOG performance status of 0, 1, or 2).
- You have not had treatment that targets BCMA (such as CAR-T) before, and you have not had a stem cell transplant from a donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
This trial tests a new combination of two drugs (teclistamab and iberdomide) for people with multiple myeloma that has come back or stopped responding to standard treatments. The goal is to see how well this combination works and whether it can help control the disease.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This trial tests a combination of immunotherapy drugs for patients with newly diagnosed, high-risk multiple myeloma. The goal is to see if this multi-target approach can improve outcomes by using the immune system to attack the cancer.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
Hear when a new Multiple Myleoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.